|
original article |
Date |
Title |
Authors All Authors |
1 |
[GO] |
2024―Sep―11 |
Structural basis for inhibition of the SARS-CoV-2 nsp16 by substrate-based dual site inhibitors |
Gints Kalnins, Laura Rudusa, Anna Bula, Diana Zelencova-Gopejenko, Olga Bobileva, Mihails Sisovs, et al. (+4) Kaspars Tars, Aigars Jirgensons, Kristaps Jaudzems, Raitis Bobrovs |
2 |
[GO] |
2024―Aug―14 |
Developing Allosteric Inhibitors of SARS-CoV-2 RNA-dependent RNA polymerase |
Artem Chayka, Matěj Danda, Alžběta Dostálková, Vojtěch Spiwok, Anna Klimešová, Marina Kapisheva, et al. (+5) Michala Zgarbová, Jan Weber, Tomáš Ruml, Michaela Rumlová, Zlatko Janeba |
3 |
[GO] |
2024―Jul―08 |
Discovery of Fluorescent Naturally-occurring Inhibitor of SARS-CoV-2 Main Protease By AIE Fluorescent Probe |
Chong-Jing Zhang, Hao Lin |
4 |
[GO] |
2024―May―17 |
Front Cover: Identification of Potential Inhibitors of the SARS-CoV-2 NSP13 Helicase via Structure-Based Ligand Design, Molecular Docking and Nonequilibrium Alchemical Simulations (ChemMedChem 10/2024) |
Giorgio Di Paco, Marina Macchiagodena, Piero Procacci |
5 |
[GO] |
2024―Mar―08 |
Identification of Potential inhibitors of the SARS-CoV-2 NSP13 Helicase via Structure-Based Ligand Design, Molecular Docking and Nonequilibrium Alchemical Simulations |
Giorgio Di Paco, Marina Macchiagodena, Piero Procacci |
6 |
[GO] |
2023―May―30 |
A patent review on SARS coronavirus papain-like protease (PLpro) inhibitors. |
C. S. Brian Chia, Siew Pheng Lim |
7 |
[GO] |
2023―Feb―22 |
A critical study on acylating and covalent reversible fragment inhibitors of SARS-CoV-2 main protease targeting the S1-site with pyridine |
Rebekka Wamser, Szymon Pach, Christoph Arkona, Morris Baumgardt, Umer Bin Abdul Aziz, Andreas C. Hocke, et al. (+2) Gerhard Wolber, Jörg Rademann |
8 |
[GO] |
2022―Oct―03 |
Effects of the 5'-Triphosphate Metabolites of Ribavirin, Sofosbuvir, Vidarabine, and Molnupiravir on CTP Synthase. Implications for Repurposing Antiviral Agents Against SARS-CoV-2 |
Thomas D. Gillis, Stephen L. Bearne |
9 |
[GO] |
2022―Sep―27 |
Recent Drug Development and Medicinal Chemistry Approaches for the Treatment of SARS-CoV-2 and Covid-19 |
Arun K Ghosh, Jennifer L. Mishevich, Andrew Mesecar, Hiroaki Mitsuya |
10 |
[GO] |
2022―Aug―29 |
Toward a Home Test for COVID 19 Diagnosis: DNA Machine for Amplification-Free SARS-CoV-2 Detection in Clinical Samples |
Ahmed A. ElDeeb, Sofia S. Zablotskaya, Maria S. Rubel, Moustapha A. Y. Nour, Liubov I. Kozlovskaya, Anna A. Shtro, et al. (+2) Andrey B. Komissarov, Dmitry M Kolpashchikov |
11 |
[GO] |
2022―Jun―20 |
Corrigendum: Promising Therapeutic Approach for SARS-CoV-2 Infections by Using a Rutin-Based Combination Therapy |
Monika Mazik |
12 |
[GO] |
2022―May―02 |
One Solution for All: Searching for Universal Aptamers for Constantly Mutating Spike Proteins of SARS-CoV-2 |
Jiuxing Li, Zijie Zhang, Ryan Amini, Yingfu Li |
13 |
[GO] |
2022―Apr―30 |
Promising therapeutic approach for SARS-CoV-2 infection by using a rutin-based combination therapy |
Monika Mazik |
14 |
[GO] |
2022―Feb―21 |
Synthesis and In Vitro Study of Artemisinin/Synthetic Peroxide Based Hybrid Compounds against SARS-CoV-2 and Cancer |
Lars Herrmann, Ivan A. Yaremenko, Aysun Çapcı, Julia Struwe, Dhanir Tailor, Arpit Dheeraj, et al. (+8) Jan Hodek, Yulia Yu. Belyakova, Peter Radulov, Jan Weber, Sanjay V. Malhotra, Alexander O. Terent'ev, Lutz Ackermann, Svetlana B. Tsogoeva |
15 |
[GO] |
2022―Feb―08 |
Corrigendum: Drug Repurposing for the SARS-CoV-2 Papain-Like Protease |
Chia-Chuan Cho, Shuhua G. Li, Tyler J. Lalonde, Kai S. Yang, Ge Yu, Yuchen Qiao, et al. (+2) Shiqing Xu, Wenshe Ray Liu |
16 |
[GO] |
2022―Feb―03 |
Synthesis of Dihydrobenzofuro[3,2-b]chromenes as a potential 3CLpro inhibitors of SARS-CoV-2: A molecular docking and dynamics simulation study |
Sudip Gorai, Vivek Junghare, Kshama Kundu, Sowmomita Gharui, Mukesh Kumar, Birija Sankar Patro, et al. (+3) Sandip K. Nayak, Saugata Hazra, Soumyaditya Mula |
17 |
[GO] |
2022―Jan―27 |
Mass spectrometric assays reveal discrepancies in inhibition profiles for the SARS-CoV-2 papain-like protease |
Lennart Brewitz, Jos J. A. G. Kamps, Petra Lukacik, Claire Strain-Damerell, Yilin Zhao, Anthony Tumber, et al. (+4) Tika R. Malla, Allen M. Orville, Martin A. Walsh, Christopher Schofield |
18 |
[GO] |
2022―Jan―07 |
Front Cover: MPI8 is Potent against SARS-CoV-2 by Inhibiting Dually and Selectively the SARS-CoV-2 Main Protease and the Host Cathepsin L (ChemMedChem 1/2022) |
Xinyu R. Ma, Yugendar R. Alugubelli, Yuying Ma, Erol C. Vatansever, Danielle A. Scott, Yuchen Qiao, et al. (+3) Ge Yu, Shiqing Xu, Wenshe Ray Liu |
19 |
[GO] |
2021―Dec―10 |
Corrigendum: New Pyrazine Conjugates: Synthesis, Computational Studies, and Antiviral Properties against SARS-CoV-2 |
Israa A. Seliem, Adel S. Girgis, Yassmin Moatasim, Ahmed Kandeil, Ahmed Mostafa, Mohamed A. Ali, et al. (+2) Mohamed S. Bekheit, Siva S. Panda |
20 |
[GO] |
2021―Dec―06 |
Front Cover: Bithiazole Inhibitors of Phosphatidylinositol 4-Kinase (PI4KIIIβ) as Broad-Spectrum Antivirals Blocking the Replication of SARS-CoV-2, Zika Virus, and Human Rhinoviruses (ChemMedChem 23/2021) |
Maria Grazia Martina, Ilaria Vicenti, Lisa Bauer, Emmanuele Crespan, Enrico Rango, Adele Boccuto, et al. (+10) Noemi Olivieri, Matteo Incerti, Marleen Zwaagstra, Marika Allodi, Simona Bertoni, Elena Dreassi, Maurizio Zazzi, Frank J. M. Kuppeveld, Giovanni Maga, Marco Radi |
21 |
[GO] |
2021―Dec―01 |
Structure-Activity Studies Reveal Scope for Optimisation of Ebselen-Type Inhibition of SARS-COV-2 Main Protease |
Siegfried T. D Thun-Hohenstein, Timothy F Suits, Tika R Malla, Anthony Tumber, Lennart Brewitz, Eidarus Salah, et al. (+2) Hani Choudhry, Christopher Schofield |
22 |
[GO] |
2021―Oct―15 |
A patent review on SARS coronavirus main protease (3CLpro) inhibitors. |
C. S. Brian Chia, Weijun Xu, Pearly Shuyi Ng |
23 |
[GO] |
2021―Aug―23 |
Drug Repurposing for the SARS-CoV-2 Papain-Like Protease |
Wenshe Liu, Chia-Chuan Cho, Shuhua G. Li, Tyler J. Lalonde, Kai S. Yang, Ge Yu, et al. (+2) Yuchen Qiao, Shiqing Xu |
24 |
[GO] |
2021―Aug―12 |
Bithiazole Inhibitors of Phosphatidylinositol 4-Kinase (PI4KIIIβ) as Broad-Spectrum Antivirals Blocking the Replication of SARS-CoV-2, Zika Virus and Human Rhinoviruses |
Maria Grazia Martina, Ilaria Vicenti, Lisa Bauer, Emmanuele Crespan, Enrico Rango, Adele Boccuto, et al. (+10) Noemi Olivieri, Matteo Incerti, Marleen Zwaagstra, Marika Allodi, simona bertoni, Elena Dreassi, Maurizio Zazzi, Frank J. M. van Kuppeveld, Giovanni Maga, Marco Radi |
25 |
[GO] |
2021―Aug―05 |
New pyrazine conjugates: Synthesis, computational studies, and antiviral properties against SARS-CoV-2 |
Israa A. Seliem, Adel S. Girgis, Yassmin Moatasim, Ahmed Kandeil, Ahmed Mostafa, Mohamed A. Ali, et al. (+2) Mohamed S. Bekheit, Siva S Panda |
26 |
[GO] |
2021―Jul―09 |
MPI8 is Potent Against SARS-CoV-2 by Inhibiting Dually and Selectively the SARS-CoV-2 Main Protease and the Host Cathepsin L |
Wenshe Liu, R. Xinyu, Yugendar R. Alugubelli, Yuying Ma, Erol C. Vantasever, Danielle A. Scott, et al. (+3) Yuchen Qiao, Ge Yu, Shiqing Xu |
27 |
[GO] |
2021―Jul―06 |
Front Cover: Inspecting the Mechanism of Fragment Hits Binding on SARS-CoV-2 M
pro
by Using Supervised Molecular Dynamics (SuMD) Simulations (ChemMedChem 13/2021) |
Maicol Bissaro, Giovanni Bolcato, Matteo Pavan, Davide Bassani, Mattia Sturlese, Stefano Moro |
28 |
[GO] |
2021―Jun―18 |
In silico characterization of masitinib interaction with SARS-CoV-2 main protease |
Ulises Martínez-Ortega, Diego I. Figueroa-Figueroa, Francisco Hernández-Luis, Rodrigo Aguayo-Ortiz |
29 |
[GO] |
2021―Jun―01 |
Poly-L-lysine Glycoconjugates Inhibit DC-SIGN-mediated Attachment of Pandemic Viruses |
Beat Ernst, Jonathan Cramer, Butrint Aliu, Xiaohua Jiang, Timothy Sharpe, Lijuan Pang, et al. (+2) Adrian Hadorn, Said Rabbani |
30 |
[GO] |
2021―Apr―03 |
Science’s response to CoVID-19 |
Yimon Aye, Marcus Long |
31 |
[GO] |
2021―Apr―02 |
Inspecting the mechanism of fragment hit binding on SARS-CoV-2 Mpro by using supervised molecular dynamics (SuMD) simulations. |
Maicol Bissaro, Giovanni Bolcato, Matteo Pavan, Davide Bassani, Mattia Sturlese, Stefano Moro |
32 |
[GO] |
2021―Jan―22 |
Front Cover: Structure-Activity Relationships of Benzamides and Isoindolines Designed as SARS-CoV Protease Inhibitors Effective against SARS-CoV-2 (2/2021) |
Armin Welker, Christian Kersten, Christin Müller, Ramakanth Madhugiri, Collin Zimmer, Patrick Müller, et al. (+6) Robert Zimmermann, Stefan Hammerschmidt, Hannah Maus, John Ziebuhr, Christoph Sotriffer, Tanja Schirmeister |
33 |
[GO] |
2020―Dec―22 |
Action of dipeptidyl peptidase-4 inhibitors on SARS-CoV-2 main protease |
Thomas Klein, Herbert Nar, Gisela Schnapp, Oliver Hucke, Timothy C Hardman |
34 |
[GO] |
2020―Dec―07 |
A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors |
Wenshe Liu, Kai Yang, Xinyu Ma, Yuying Ma, Yugendar Alugubelli, Danielle Scott, et al. (+16) Erol vatansever, Aleksandra Drelich, Banumathi Sankaran, Zhi Geng, Lauren Blankenship, Hannah Ward, Yan Sheng, Jason Hsu, Kaci Kratch, Baoyu Zhao, Hamed Hayatshahi, Jin Liu, Pingwei Li, Carol Fierke, Chien-Te Tseng, Shiqing Xu |
35 |
[GO] |
2020―Sep―16 |
SAR of novel benzamides and isoindolines, designed as SARS-CoV protease inhibitors - effective against SARS-CoV-2 |
Armin Welker, Christian Kersten, Christin Müller, Ramakanth Madhugiri, Collin Zimmer, Patrick Müller, et al. (+6) Robert Alexander Zimmermann, Stefan Hammerschmidt, Hannah Maus, John Ziebuhr, Christoph Sotriffer, Tanja Schirmeister |
36 |
[GO] |
2020―Jul―23 |
Targeting SARS-CoV-2 RBD interface: a supervised computational data-driven approach to identify potential modulators |
Maria Rita Gulotta, Jessica Lombino, Ugo Perricone, Giada De Simone, Nedra Mekni, Maria De Rosa, et al. (+2) Patrizia Diana, Alessandro Padova |
37 |
[GO] |
2020―Jul―14 |
ACE2, the Receptor that Enables the Infection by SARS-CoV-2: Biochemistry, Structure, Allostery and Evaluation of the Potential Development of ACE2 Modulators |
Lissy Z.F. Gross, Mariana Sacerdoti, Albrecht Piiper, Stefan Zeuzem, Alejandro E. Leroux, Ricardo M. Biondi |
38 |
[GO] |
2020―Apr―23 |
Drug Development and Medicinal Chemistry Efforts Toward SARS-Coronavirus and Covid-19 Therapeutics |
Arun K Ghosh, Margherita Brindisi, Dana Shahabi, Mackenzie E. Chapman, Andrew D. Mesecar |